AI assistant
LIGAND PHARMACEUTICALS INC — Director's Dealing 2021
Feb 10, 2021
31289_dirs_2021-02-09_002f0792-2e1f-4543-bd22-1219b9c4c3a8.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: LIGAND PHARMACEUTICALS INC (LGND)
CIK: 0000886163
Period of Report: 2021-02-05
Reporting Person: HIGGINS JOHN L (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-02-05 | Common Stock | M | 54666 | $14.47 | Acquired | 340696 | Direct |
| 2021-02-05 | Common Stock | S | 54666 | $203.4032 | Disposed | 286030 | Direct |
| 2021-02-05 | Common Stock | M | 60000 | $10.05 | Acquired | 346030 | Direct |
| 2021-02-05 | Common Stock | F | 2970 | $203.03 | Disposed | 343060 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-02-05 | Non-Qualified Stock Option (right to buy) | $10.05 | M | 60000 | Disposed | 2021-02-17 | Common Stock (60000) | Direct |
| 2021-02-05 | Non-Qualified Stock Option (right to buy) | $14.47 | M | 54666 | Disposed | 2022-02-09 | Common Stock (54666) | Direct |
Footnotes
F1: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 10, 2020, in accordance with Rule 10b5-1.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $200.00 to $201.29, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: Represents previously-owned shares delivered to the Issuer in payment of the exercise price of the stock options.
F4: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/17/11.
F5: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/09/12.